Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCD-100 plus platinum-based chemotherapy with or without bevacizumab versus placebo in first-line advanced cervical cancer
2019-000623-40Phase 3Terminated
- Sponsor
- BIOCAD
- Start
- Oct 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Cervical Cancer (CC) comparing Prolgolimab arm with Placebo arm (2 arms). Primary endpoint: overall survival. Started Oct 2019; status: terminated.
02
Drugs
prolgolimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on 2019-000623-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000623-40.